Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Arcos Dorados Q3 Earnings Beat Estimates

Arcos Dorados Holdings Inc (NYSE:ARCO) reported third-quarter FY22 sales growth of 27% year-on-year to $921.7 million, beating the consensus of $902.19…
byShivani Kumaresan
November 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Arcos Dorados Holdings Inc (NYSE:ARCO) reported third-quarter FY22 sales growth of 27% year-on-year to $921.7 million, beating the consensus of $902.19 million.
  • Excluding Venezuela, Consolidated revenue totaled $916.3 million, rising 26.7% in U.S. dollars and 38.9% in constant currency.
  • Systemwide comparable sales grew 34.2% Y/Y, Excluding Venezuela, driven primarily by higher guest traffic and market share gains across the region.
  • The operating margin was 8%, and the operating income for the quarter was $73.9 million.
  • Adjusted EBITDA for the quarter was $102.65 million with an adjusted EBITDA margin of 11.2%, down 120 basis points versus last year.
  • EPS of $0.22 beat the analyst consensus of $0.11.
  • The company held $319.1 million in cash and equivalents as of September 30, 2022.
  • Price Action: ARCO shares are trading higher by 7.67% at $7.86 on the last check Wednesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19

By Benzinga Newsdesk
April 20, 8:07 AM
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Michigan Medicine, a part of the

VTVT